Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Alexander C. J. van Akkooi et al.|The Lancet Oncology|2021Cited by 389
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab TherapyPaolo A. Ascierto, Victoria Atkinson, Georgina V. Long et al.|JAMA Oncology|2018Cited by 345
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanomaJulie Westerlin Kjeldsen, Inge Marie Svane|Nature Medicine|2021Cited by 205
Predictors of responses to immune checkpoint blockade in advanced melanomaNicolas Jacquelot, Laurence Zitvogel, María P. Roberti et al.|Nature Communications|2017Cited by 201
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish studyMaria D’Souza, Morten Schou, Dorte Nielsen et al.|European Heart Journal|2020Cited by 166